Pirfenidone improves adipose dysfunction and obesity-driven steatohepatitis via mTORC1 signaling
Pirfenidone ameliorates obesity-driven steatohepatitis by differentially remodeling adipose tissue through mTORC1 signaling, specifically inhibiting lipogenesis in subcutaneous fat and suppressing fibrosis in visceral fat to improve liver health.